Aquestive Therapeutics, Inc.
AQST · XNASCIK 1398733fmd_1AZVW31WDV7NM915G5GVQTC10RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 67 | 67 | 53 | 46 | 51 | 48 | 51 | 58 | 45 |
| Cost of revenue | – | – | 20 | 13 | – | 19 | 21 | 18 | 19 |
| Gross profit | – | – | 32 | 33 | – | 28 | 30 | 40 | 26 |
| Research and development | 22 | 23 | 21 | 20 | 17 | 17 | 13 | 20 | 17 |
| Selling, general and administrative | 25 | 72 | 64 | 56 | 53 | 53 | 32 | 50 | 80 |
| Total operating expenses | 67 | 116 | 105 | 89 | 86 | 90 | – | – | – |
| Operating income | (0) | (49) | (53) | (43) | (35) | (42) | (15) | (31) | (71) |
| Interest expense | 8 | 8 | 9 | 11 | 10 | 7 | 6 | 11 | 11 |
| Interest and investment income | 0 | 1 | 1 | 0 | 0 | 0 | – | – | – |
| Income before taxes | (9) | (61) | (66) | (56) | (71) | (54) | (8) | (44) | (84) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | (9) | (61) | (66) | (56) | (71) | (54) | (8) | (44) | (84) |
| Net income | (9) | (61) | (66) | (56) | (71) | (54) | (8) | (44) | (84) |
| Net income to common shareholders | (11) | (61) | – | – | – | – | – | – | – |